{"id":"W4286294392","doi":"10.1200/jco.2022.40.16_suppl.11541","title":"Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Tolerability; Sunitinib; Adverse effect; Internal medicine; Clinical endpoint; Quality of life (healthcare); GiST; Gastroenterology; Surgery; Randomized controlled trial; Cancer; Stromal cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001974312,0.000600638,0.001948726,0.0002169067,0.0003017226,0.0007009613,0.0004136553,0.0008545939,0.003774248],"category_scores_gemma":[0.001398928,0.0002758016,0.001558669,0.0002629514,0.0005759557,0.0008287075,0.000299425,0.001630814,0.0004515628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006258854,"about_ca_system_score_gemma":0.000667791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003446037,"about_ca_topic_score_gemma":0.001161501,"domain_scores_codex":[0.9993969,0.0003207872,0.0000362579,0.0001039446,0.00006102424,0.00008110963],"domain_scores_gemma":[0.9990399,0.0002306691,0.0002762378,0.00006547846,0.00004192768,0.000345756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8993673,0.02235287,0.01201226,0.0006787424,0.001747941,0.0001019015,0.0001721485,0.001014981,0.01101104,0.00009016567,0.001299095,0.05015149],"study_design_scores_gemma":[0.3941193,0.5463769,0.05240141,0.00004052876,0.001345268,0.0002962778,0.0000947799,0.001417215,0.001806426,0.0001668754,0.001884759,0.00005026249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996711,0.00147434,0.0002069758,0.00008287235,0.00003200604,0.0004134925,0.0005021915,0.00002580604,0.0005513123],"genre_scores_gemma":[0.9963491,0.0005739292,0.0005400804,0.0002980346,0.00008108243,0.0007134724,0.0008458751,0.000008582182,0.0005897396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003774248,"threshold_uncertainty_score":0.01262617,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2290711850459004,"score_gpt":0.5292887835417361,"score_spread":0.3002175984958357,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}